Latest Commercial Growth News

Adisyn Ltd reshuffles leadership with Kevin Crofton stepping up as Executive Chairman while Arye Kohavi moves to a Non-Executive Director role, signalling a strategic pivot to accelerate commercial execution in semiconductor technology.

EBR Systems has secured ISO 13485 certification for its new Santa Clara manufacturing site, paving the way for a 500% increase in WiSE System production pending FDA approval expected by year-end.

Immuron Limited has inked an exclusive US distribution deal for PROIBS®, a European-certified medical device targeting abdominal discomfort, marking a key step in its digestive health portfolio growth.

Activeport Group Ltd’s FY26 results show a 36% revenue decline to $6.15 million and a net loss of $14.7 million, driven by strategic shifts towards recurring software revenue and AI infrastructure orchestration. The company launched its own national network in Australia and expanded internationally with new subsidiaries and leadership hires.

Microba Life Sciences delivered a mixed FY26, with overall revenue slipping 5.8% to $14.76 million and a statutory loss widening 38.7% to $20.7 million. The company’s strategic pivot to core microbiome testing paid off with a 92% surge in core testing revenue and record test volumes in Australia and the UK. Despite the headline loss, underlying loss improved 11% thanks to cost cuts and AI-driven efficiencies. Microba is gearing up for the October launch of its GI Navigator diagnostic and targeting cash flow break-even on a run-rate basis in calendar 2027.

Atomo Diagnostics lifted revenue 41% to AUD 5.33 million for FY26, cutting its loss by 29% to AUD 3.51 million, driven by HIV self-testing growth and a key US partnership. Leadership changes signal a strategic pivot as the company eyes global expansion.

IperionX has landed a second U.S. Army task order worth US$11.5 million to expand its industrial-scale titanium manufacturing capacity in Virginia, advancing its integrated powder-to-part platform for defense applications.

Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.

Winton Land’s governance is under strain after independent directors Steven Joyce and Guy Fergusson resigned citing conflicts with the majority shareholder. The board must urgently appoint new independent directors to maintain NZX compliance and avoid potential trading suspension.

Winton Land reported a 120% rise in net profit to $22.7 million in FY26, driven by increased residential settlements and full-year trading at its hospitality venues, despite economic headwinds and leadership changes.

Brisbane Broncos Limited reported a 33% jump in half-year profit before tax to $11.57 million, fuelled by higher crowds, membership, and merchandise sales despite a slight dip in ARLC funding.

Audeara Limited has raised $1.26 million through a two-tranche share placement to back its expanding technology licensing and retail channels, following a year of revenue growth and reduced cash burn.